SGLT2抑制剂治疗心力衰竭:一种新作用机制的提出
本文提出SGLT2抑制剂对心力衰竭的获益可能源于抑制钠-氢交换体而非降糖或渗透性利尿。在肾脏,SGLT2与钠-氢交换体功能交互,后者的活性在心力衰竭患者中显著增加,可能导致利尿剂抵抗。在心脏,恩格列净抑制钠-氢交换,可能减少心肌损伤、肥厚、纤维化、重构和收缩功能障碍。
要点
- SGLT2抑制剂对心衰的获益不能仅用降糖或渗透性利尿解释
- 肾脏钠-氢交换体活性在心衰中增加,或致利尿剂抵抗
- 心脏钠-氢交换抑制可能减少心肌损伤和重构
核心结论
- SGLT2抑制剂的心衰获益可能由抑制钠-氢交换介导,而非葡萄糖重吸收效应。
研究设计与样本
- 本文为叙述性综述,基于EMPA-REG Outcomes等研究观察提出新机制假说。
主要发现
- 在EMPA-REG Outcomes中,恩格列净长期治疗预防了致死性和非致死性心衰事件,但未降低心肌梗死或卒中风险。
- 在肾脏,SGLT2与钠-氢交换体功能交互,后者负责滤过后大部分钠的肾小管重吸收。
- 心衰患者中钠-氢交换体活性显著增加,可能参与利尿剂抵抗和内生利钠肽抵抗。
- 在心脏,恩格列净似乎抑制钠-氢交换,可能减少心肌损伤、肥厚、纤维化、重构和收缩功能障碍。
- SGLT2抑制剂降低血压、体重和液体潴留及改善肾功能,可能缓解射血分数保留心衰的主要病理生理异常。
临床怎么用
- 该假说提示SGLT2抑制剂的获益机制不同于传统降糖药,临床决策不应仅基于降糖效果。
- 未来大规模结局试验的设计和分析应纳入非糖尿病慢性心衰患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducing the risk of the development or progression of heart failure. In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [EMPA-REG Outcomes], long-term treatment with empagliflozin prevented fatal and nonfatal heart failure events but did not reduce the risk of myocardial infarction or stroke in diabetic patients. OBSERVATIONS: The beneficial effect of SGLT2 inhibitors on heart failure cannot be explained by their actions on glycemic control or as osmotic diuretics. Instead, in the kidneys, SGLT2 functionally interacts with the sodium-hydrogen exchanger, which is responsible for the majority of sodium tubular reuptake following filtration. The activity of sodium-hydrogen exchanger is markedly increased in patients with heart failure and may be responsible for both resistance to diuretics and to endogenous natriuretic peptides. In addition, in the heart, empagliflozin appears to inhibit sodium-hydrogen exchange, which may in turn lead to a reduction in cardiac injury, hypertrophy, fibrosis, remodeling, and systolic dysfunction. Furthermore, the major pathophysiological derangements of heart failure and a preserved ejection fraction may be mitigated by the actions of SGLT2 inhibitors to reduce blood pressure, body weight, and fluid retention as well as to improve renal function. The benefits of spironolactone in patients with heart failure with either a reduced or a preserved ejection fraction may also be attributable to the actions of the drug to inhibit the sodium-hydrogen exchange mechanism. CONCLUSIONS AND RELEVANCE: The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption. This hypothesis has important implications for the design and analysis of large-scale outcomes trials involving diabetic or nondiabetic patients with chronic heart failure.
引用
- Packer M, Anker SD, Butler J, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA Cardiol. 2017. PMID: 28768320. doi:10.1001/jamacardio.2017.2275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。